Ovid Therapeutics Bolsters Executive Team with New CBO, R&D Advisor, and Key Promotions
OVID has more than doubled off its 52-week low of $0.331.
Summary
Ovid Therapeutics announced significant executive leadership changes, including the appointment of Kevin Norrett as Chief Business Officer and Eliseo Salinas as Executive R&D Advisor, alongside the promotions of Charles Carter to CFO and Victoria Fort to Chief Strategy Officer. Norrett, who most recently served as Chief Business Officer at Soleno Therapeutics where he led its acquisition by Neurocrine Biosciences, brings a strong background in strategic partnerships and M&A. Charles Carter, with more than 30 years of experience across finance, strategy, and operational leadership, succeeds Jeffrey Rona as CFO, with Rona transitioning from finance roles to remain a long-term advisor through 2027. Eliseo Salinas offers decades of drug development experience, further strengthening the team. These strategic hires and promotions follow recent financing activities that substantially increased the company's cash reserves, as detailed in its Q1 2026 financial results and warrant exercises, positioning Ovid to accelerate pipeline progress and explore collaborations.
At the time of this announcement, OVID was trading at $2.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $515.1M. The 52-week trading range was $0.33 to $3.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.